ZILRETTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zilretta, and when can generic versions of Zilretta launch?
Zilretta is a drug marketed by Pacira Pharms Inc and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-one patent family members in twenty-two countries.
The generic ingredient in ZILRETTA is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zilretta
A generic version of ZILRETTA was approved as triamcinolone acetonide by TARO on October 1st, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZILRETTA?
- What are the global sales for ZILRETTA?
- What is Average Wholesale Price for ZILRETTA?
Summary for ZILRETTA
International Patents: | 51 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 17 |
Patent Applications: | 4,308 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZILRETTA |
What excipients (inactive ingredients) are in ZILRETTA? | ZILRETTA excipients list |
DailyMed Link: | ZILRETTA at DailyMed |
![ZILRETTA drug patent expirations Drug patent expirations by year for ZILRETTA](/p/graph/s/t/ZILRETTA-patent-expirations.png)
![Drug Prices for ZILRETTA](/p/graph/drug-price/ZILRETTA.png)
Recent Clinical Trials for ZILRETTA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ohio State University | Phase 4 |
Sorrento Therapeutics, Inc. | Phase 2 |
ROC Foundation | Phase 4 |
US Patents and Regulatory Information for ZILRETTA
ZILRETTA is protected by two US patents.
Patents protecting ZILRETTA
Corticosteroids for the treatment of joint pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Corticosteroids for the treatment of joint pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pacira Pharms Inc | ZILRETTA | triamcinolone acetonide | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | 208845-001 | Oct 6, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pacira Pharms Inc | ZILRETTA | triamcinolone acetonide | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | 208845-001 | Oct 6, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZILRETTA
See the table below for patents covering ZILRETTA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2739287 | CORTICOSTÉROÏDES DESTINÉS À TRAITER UNE DOULEUR ARTICULAIRE (CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN) | ⤷ Sign Up |
Japan | 5873492 | ⤷ Sign Up | |
Canada | 2807150 | CORTICOSTEROIDES POUR LE TRAITEMENT DE LA DOULEUR ARTICULAIRE (CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |